Routine use of the direct thrombin inhibitor bivalirudin for off-pump coronary artery bypass grafting is safe and effective

Heart Surgery Forum

Volumn 11, Issue 1, 2008, Pages 24-29

  Palmer, George J ^a,e   Sankaran, Iyer S ^b   Sparkman, Gary M ^b   Koster, Andreas ^c   Dyke, Cornelius M ^d   Ebra, George ^a  

^a FLORIDA HOSPITAL   (United States)

^b Central Florida Regional Hospital   (United States)

^c DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^d Gaston Memorial Hospital   (United States)

^e Cardiovascular Surgeons   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; HIRULOG; PROTAMINE; THROMBIN INHIBITOR;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CARDIOPULMONARY BYPASS; CARDIOVASCULAR PARAMETERS; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; FORWARD HEART FAILURE; GRAFT PATENCY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; KIDNEY FAILURE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OFF PUMP CORONARY SURGERY; OUTCOME ASSESSMENT; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; REOPERATION; STROKE;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CORONARY ARTERY BYPASS; CORONARY ARTERY BYPASS, OFF-PUMP; FEMALE; FIBRINOLYTIC AGENTS; HEALTH STATUS INDICATORS; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; POSTOPERATIVE COMPLICATIONS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBIN; TREATMENT OUTCOME;

EID: 39449090371     PISSN: 10983511     EISSN: None     Source Type: Journal    
DOI: 10.1532/HSF98.20071173     Document Type: Article

References (25)

1. Angelini GD, Taylor FC, Reeves BC, Ascione R. 2002. Early and midterm outcome after off-pump and on-pump surgery in Beating Heart Against Cardioplegic Arrest Studies (BHACAS 1 and 2): a pooled analysis of two randomized controlled trials. Lancet 359:1194-9.
2. Bartholomew JR, Begelman SM, Almahameed A. 2005. Heparin-induced thrombocytopenia: principles for early recognition and management. Cleve Clin J Med 72(suppl 1):S31-6.
3. Bates SM, Weitz JI. The mechanism of action of direct thrombin inhibitors. 2000. J Invasive Cardiol 12:27-32.
4. Bennett-Guerrero E, Slaughter TF, White WD, et al. 2005. Preoperative anti-PF4/H antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg 130:1567-72.
5. Bott JN, Reddy K, Krick S. 2003. Bivalirudin use in off-pump myocardial revascularization in patients with heparin-induced thrombocytopenia. Ann Thorac Surg 76:273-5.
6. Cohn LH. Fifty years of open-heart surgery. 2003. Circulation 107:2168-70.
7. D'Ancona G, Donias HW, Karamanoukian RL, Bergsland J, Karamanoukian HL. 2001. OPCAB therapy survey: off-pump clopidogrel, aspirin or both therapy survey. Heart Surg Forum 4:354-8.
8. Dyke CM, Smedira NG, Koster A, et al. 2006. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: The EVOLUTION-ON study. J Thorac Cardiovasc Surg 131:533-9.
9. Edmunds LH Jr. 1995. Why cardiopulmonary bypass makes patients sick: strategies to control the blood-synthetic surface interface. Adv Card Surg 6:131-67.
10. Francis JL, Palmer GJ, Moroose R, Drexler A. 2003. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg 75:17-22.
11. Khan NE, DeSouza A, Mister R, et al. 2004. A randomized comparison of off-pump and on-pump multi-vessel coronary artery bypass surgery. N Engl J Med 350:21-8.
12. Kirklin J, Westaby S, Blackstone, et al. 1983. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 86:845-57.
13. Koster A, Spiess B, Chew DP, et al. 2004. Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Am J Cardiol 93:356-9.
14. Lincoff AM, Bittl JA, Harrington RA, et al. 2003. Bivalirudin and provision glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289:853-63.
15. Matar F, Donoghue C, Rossi P. 2006. Angiographic and clinical outcomes of bivalirudin versus heparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Can J Cardiol 22(13):1139-45.
16. Merry AF, Raudkivi PJ, Middleton NG, et al. 2004. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg 77:925-31.
17. Puskas JD, Williams WH, Duke PG, et al. 2003. Off-pump coronary artery bypass grafting provides complete revascularization with reduced myocardial injury, transfusion requirements and length of stay: a prospective randomized comparison of two hundred unselected patients undergoing off-pump versus conventional coronary artery bypass grafting. J Thorac Cardiovasc Surg 125:797-808.
18. Ranucci M, Frigiola A, Menicanti L, Cazzaniga A, Soro G, Isgro G. 2001. Risk factors for fatal myocardial infarction after coronary bypass surgery. Eur J Anaesthesiol 18:322-9.
19. Sedrakyan A, Wu AW, Parashar A, Bass EB, Treasure T. 2006. Off-pump surgery is associated with reduced occurrence of stroke and other morbidity as compared with traditional coronary artery bypass grafting: a meta-analysis of systematically reviewed trials. Stroke 37: 2759-69.
20. Smedira NG, Dyke CM, Koster A, et al. 2006. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: The results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg 131:686-92.
21. Van Dijk D, Nierich AP, Jansen EWL, et al. 2001. Early outcome after off-pump versus on-pump coronary bypass surgery: results from a randomized study. Circulation 104:1761-6.
22. Warkentin TE, Greinacher A. 2003. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 76:2121-31.
23. Warkentin TE, Kelton JG. 2001. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 135:502-6.
24. Warkentin TE, Koster A. 2005. Bivalirudin: a review. Expert Opin Pharmacother 6:1349-71.
25. Williams RT, Damaraju LV, Mascelli MA, et al. 2003. Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation 107:2307-12.